<DOC>
	<DOC>NCT00410306</DOC>
	<brief_summary>This is an observational study with a drug called Nebido, a new testosterone replacement therapy, which is available for the treatment of male hypogonadism. The benefit and safety of Nebido have already been thoroughly evaluated through well controlled clinical trials. The main purpose of this observational study is to confirm the established safety profile of Nebido in daily clinical practice.</brief_summary>
	<brief_title>Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male hypogonadal patients eligible for longterm testosterone therapy who have newly been prescribed Nebido® in accordance with the terms of the marketing authorization Patients presenting with contraindications as stated in the product information</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Nebido</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Observational Study</keyword>
</DOC>